Eli Lilly (LLY) EBT (2009 - 2026)

Eli Lilly has reported EBT for 18 years, with the latest figure at $8.9 billion in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 156.08% year-over-year to $8.9 billion; the trailing twelve-month figure through Mar 2026 stood at $31.1 billion (up 128.86% YoY), and the FY2025 full-year result was $25.7 billion, up 102.93% from the prior year.
• EBT for Q1 2026 stood at $8.9 billion, up from $8.3 billion in the prior quarter.
• The five-year high for EBT was $8.9 billion in Q1 2026, with the low at $427.2 million in Q3 2023.
• Historically, EBT has averaged $3.6 billion across 5 years, with a median of $2.5 billion in 2023.
• Annual changes were most pronounced in 2023 — EBT plunged 72.71% — and 2025, when it soared 355.33%.
• Eli Lilly's EBT stood at $2.1 billion in 2022, then rose by 19.64% to $2.5 billion in 2023, then surged by 100.87% to $5.0 billion in 2024, then surged by 64.07% to $8.3 billion in 2025, then grew by 7.06% to $8.9 billion in 2026.
• The last three EBT figures came in at $8.9 billion (Q1 2026), $8.3 billion (Q4 2025), and $7.2 billion (Q3 2025), per Business Quant data.